Zevra Therapeutics (ZVRA) Non-Current Debt (2014 - 2025)
Zevra Therapeutics' (ZVRA) quarterly Non-Current Debt came in at $61.9 million in Q4 2025, up 4.07% YoY from $59.5 million in Q4 2024, and up 1.01% on a QoQ basis from $61.3 million in Q3 2025.
Zevra Therapeutics (ZVRA) Non-Current Debt (2014 - 2025) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of Non-Current Debt data on file, last reported at $61.9 million in Q4 2025.
- Quarterly Non-Current Debt rose 4.07% year-over-year to $61.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $61.9 million (up 4.07% YoY) and the FY2025 annual result came in at $61.9 million, up 4.07% from the prior year.
- Non-Current Debt rose to $61.9 million in Q4 2025, from $61.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $61.9 million in Q4 2025 to a low of $98000.0 in Q1 2021.
- A 5-year average of $40.6 million and a median of $58.3 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt surged 1074.58% — and 2025, when it gained 4.05%.
- Tracing ZVRA's Non-Current Debt over 5 years: stood at $98000.0 in 2021, then surged by 12961.22% to $12.8 million in 2022, then slumped by 60.42% to $5.1 million in 2023, then surged by 1074.58% to $59.5 million in 2024, then increased by 4.07% to $61.9 million in 2025.
- The last three Non-Current Debt figures came in at $61.9 million (Q4 2025), $61.3 million (Q3 2025), and $60.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 61.93 Mn |
| Sep 30, 2025 | 61.31 Mn |
| Jun 30, 2025 | 60.69 Mn |
| Mar 31, 2025 | 60.09 Mn |
| Dec 31, 2024 | 59.50 Mn |
| Sep 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 58.33 Mn |
| Mar 31, 2024 | 37.94 Mn |
| Dec 31, 2023 | 5.07 Mn |
| Sep 30, 2023 | 38.80 Mn |
| Mar 31, 2023 | 12.91 Mn |
| Jun 30, 2022 | 12.80 Mn |
| Mar 31, 2021 | 98,000.00 |
| Dec 31, 2020 | 391,000.00 |
| Sep 30, 2020 | 781,000.00 |
| Jun 30, 2020 | 781,000.00 |
| Dec 31, 2015 | 11.12 Mn |
| Sep 30, 2015 | 11.56 Mn |
| Jun 30, 2015 | 11.33 Mn |
| Mar 31, 2015 | 11.09 Mn |